Compare Blackstone Inc (BX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs Gilead Sciences, Inc. — how do they compare? Blackstone Inc trades at $147.55 (market cap $117.44B), while Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Blackstone Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| BX | GILD | |
|---|---|---|
Market Cap | $117.44B | $168.35B |
Sector | Financials | Health |
52-Week High | $188.68 | $155.80 |
52-Week Low | $102.12 | $110.56 |
Dividend Yield | 3.55% | 2.42% |
Enterprise Value | — | $191.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $146.44, up 3.37% today, near its recent high. The stock shows strong earnings momentum with three consecutive quarterly beats and a robust 25.85% net income margin. Technical indicators are bullish overall, though RSI levels suggest potential overbought conditions. Recent corporate activity includes a $2.5 billion investment in Air Canada's Aeroplan loyalty program, highlighting aggressive growth initiatives.
The outlook remains positive given consistent earnings outperformance and strategic acquisitions. Key risks include market sensitivity to private equity cycles and high valuation multiples. With a consensus price target of $144.00 and 63% analyst buy ratings, Wall Street sentiment is bullish, but investors should monitor execution on large deals and broader economic trends.
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
